South Carolina is currently home to 1231 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Body Composition During Cancer Treatment
NCT03784911
Recruiting
The purpose of this study is to assess how bone density and body composition changes over a cancer patient's treatment via SOZO measurements, DEXA scan (bone density and whole body composition), performance status tests, food log, urine color test, and other study assessments. These assessments will begin after cancer diagnosis but prior to intervention, and continue during treatment and at post-treatment visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2023
Locations: Prisma Health Cancer Institute Center for Integrative Oncology and Survivorship, Greenville, South Carolina
Conditions: Cancer
Register for Updates
Body Composition Post Cancer Treatment
NCT03690401
Recruiting
The purpose of this study is to assess how bone density and body composition changes after a cancer patient completes treatment and through 12-weeks post-treatment. Patients who enroll in the 12-week exercise program, Moving On, and those that do not elect to participate in the Moving On program will both be tracked, with assessments including SOZO measurements, DEXA scan (bone density and whole body composition), performance status tests, food log, urine color test, and other study assessments.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2023
Locations: Prisma Health Cancer Institute Center for Integrative Oncology and Survivorship, Greenville, South Carolina
Conditions: Cancer
Register for Updates
Neurocircuit Strategy to Decrease Cocaine Cue Reactivity
NCT04155632
Recruiting
The overarching goal of this project is to examine the effect of combining theta burst stimulation (TBS) and N-acetylcysteine (NAC) on cocaine craving and brain response to cocaine-related images.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/28/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Cocaine-Related Disorders
Register for Updates
Blue Light Cystoscopy With Cysview® Registry
NCT02660645
Recruiting
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: Lexington Medical Center, West Columbia, South Carolina
Conditions: Bladder Cancer
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Medical University of South Carolina (MUSC), Charleston, South Carolina
Conditions: Langerhans Cell Histiocytosis
Register for Updates
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
NCT04065438
Recruiting
This multicenter, prospective, single-arm clinical study will evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient has post-renal transplant recurren... Read More
Gender:
All
Ages:
75 years and below
Trial Updated:
03/09/2023
Locations: Medical University of South Carolina Children's Hospital, Charleston, South Carolina
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
NCT02235857
Recruiting
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipid... Read More
Gender:
All
Ages:
21 years and below
Trial Updated:
03/07/2023
Locations: Medical University of South Carolina Children's Hospital, Charleston, South Carolina
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
NCT03061305
Recruiting
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2023
Locations: Prisma Health Cancer Institute, Greenville, South Carolina
Conditions: Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma
Register for Updates
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348
Recruiting
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2023
Locations: Medical University of South Carolina. Hollings Cancer Center, Charleston, South Carolina
Conditions: Multiple Myeloma
Register for Updates
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: Charleston Oncology, Charleston, South Carolina
Conditions: Multiple Myeloma
Register for Updates
An mHealth Intervention for Sedentary Behavior in Pregnant Women
NCT04903574
Recruiting
Pregnancy outcomes, such as excessive gestational weight gain and gestational diabetes, are linked to long and short-term maternal and child health. Interventions aimed at improving health behaviors, such as sedentary behavior (SB; i.e., any behavior in a seated or reclining position with low energy expenditure) are attractive because they are low-cost, can be disseminated in a wide variety of populations once pregnancy begins, and do not require drugs or prescriptions. Studies have linked SB to... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: University of South Carolina, Columbia, South Carolina
Conditions: Pregnancy Related, Sedentary Behavior
Register for Updates
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
NCT05266001
Recruiting
The GRACE-2 study is a prospective, multi-center, double-blind, randomized controlled trial of the drug GM-CSF vs placebo in children with sepsis-induced multiple organ dysfunction syndrome (MODS) who have immunoparalysis with mild to moderate inflammation.
Gender:
All
Ages:
Between 1 day and 17 years
Trial Updated:
02/07/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
Register for Updates